PMID- 22017411
OWN - NLM
STAT- MEDLINE
DCOM- 20120215
LR  - 20131106
IS  - 1744-7674 (Electronic)
IS  - 1354-3776 (Linking)
VI  - 21
IP  - 11
DP  - 2011 Nov
TI  - Recent patents of dipeptidyl peptidase IV inhibitors.
PG  - 1693-741
LID - 10.1517/13543776.2011.627325 [doi]
AB  - INTRODUCTION: The serine exopeptidase DPP IV is a dual protein able to work as an 
      enzyme and an interacting protein. The incretin molecules glucagon-like peptide 1 
      (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are hydrolyzed by DPP 
      IV into inactive forms, which are unable to promote insulin secretion. Therefore, 
      DPP IV is a validated target for the treatment of type 2 diabetes mellitus 
      (T2DM), and a number of inhibitors have been reported in the literature as 
      antidiabetic drugs. AREAS COVERED: DPP IV inhibitor patents from 2006 are 
      included in this review. Documents are classified into chemical groups depending 
      on the main claim. Groups are: i) pyrrolidines and thiazolidines; ii) 
      cyclohexanes, piperidines, piperazines, pyridines and pyrimidines; iii) fused 
      5-carbon cycles; iv) pyridine, pyrimidine and pyrazine-based bicyclic structures; 
      v) indoles, condensed-imidazoles and xanthines; vi) pyrido-pyrimidines, 
      quinolones, isoquinolines, quinozalines, quinoxalines, naphthyridines, quinolones 
      and quinazolinones; vii) benzoquinolizines, fused aminopiperidines and fused 
      triazoles; viii) other heterocyclic structures and ix) peptidomimetics. EXPERT 
      OPINION: Research in finding new DPP IV inhibitors is intense, despite the number 
      of reported molecules. This is mainly because marketed compounds have been 
      approved in the last 5 years and long-term side effects have not been detected. 
      The perfect inhibitor for the T2DM treatment would therefore be a molecule that 
      inhibits GLP-1 and GIP degradation by DPP IV, but does not affect the activity of 
      the protease in other substrates, nor disturbs the communication of DPP IV with 
      other proteins.
FAU - Mendieta, Laura
AU  - Mendieta L
AD  - Institute for Research in Biomedicine, Barcelona - Chemistry and Molecular 
      Pharmacology, Spain.
FAU - Tarrago, Teresa
AU  - Tarrago T
FAU - Giralt, Ernest
AU  - Giralt E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Expert Opin Ther Pat
JT  - Expert opinion on therapeutic patents
JID - 9516419
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - EC 3.4.14.5 (DPP4 protein, human)
RN  - EC 3.4.14.5 (Dipeptidyl Peptidase 4)
SB  - IM
MH  - Animals
MH  - Diabetes Mellitus, Type 2/*drug therapy/physiopathology
MH  - Dipeptidyl Peptidase 4/drug effects/metabolism
MH  - Dipeptidyl-Peptidase IV Inhibitors/adverse effects/*pharmacology/therapeutic use
MH  - Drug Delivery Systems
MH  - Drug Design
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects/*pharmacology/therapeutic use
MH  - Patents as Topic
EDAT- 2011/10/25 06:00
MHDA- 2012/02/16 06:00
CRDT- 2011/10/25 06:00
PHST- 2011/10/25 06:00 [entrez]
PHST- 2011/10/25 06:00 [pubmed]
PHST- 2012/02/16 06:00 [medline]
AID - 10.1517/13543776.2011.627325 [doi]
PST - ppublish
SO  - Expert Opin Ther Pat. 2011 Nov;21(11):1693-741. doi: 
      10.1517/13543776.2011.627325.